Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD.
Blood. 2017 Jun 29;129(26):3403-3406. doi: 10.1182/blood-2017-05-782292. Epub 2017 May 25.
Midostaurin was recently approved by the US Food and Drug Administration for the treatment of -mutant acute myeloid leukemia (AML). This is the first drug to receive regulatory approval for AML in the United States since the year 2000. Midostaurin is a small-molecule kinase inhibitor with activity against the receptor tyrosine kinase FLT3, and its approval will hopefully mark the beginning of an era of targeted agents for the treatment of molecularly defined subtypes of AML.
米哚妥林最近获得美国食品和药物管理局批准，用于治疗 -突变型急性髓细胞白血病（AML）。这是自 2000 年以来美国首个获得 AML 监管批准的药物。米哚妥林是一种小分子激酶抑制剂，对受体酪氨酸激酶 FLT3 具有活性，其批准有望标志着靶向治疗 AML 分子定义亚型的新时代的开始。
